Association between suPAR and cardiac diastolic dysfunction among patients with preserved ejection fraction.

Tomohiro Fujisaka, Shu-Ichi Fujita, Daichi Maeda, Kensaku Shibata, Hideaki Takahashi, Hideaki Morita, Yoshihiro Takeda, Takahide Ito, Koichi Sohmiya, Masaaki Hoshiga, Nobukazu Ishizaka
Author Information
  1. Tomohiro Fujisaka: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  2. Shu-Ichi Fujita: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  3. Daichi Maeda: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  4. Kensaku Shibata: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  5. Hideaki Takahashi: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  6. Hideaki Morita: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  7. Yoshihiro Takeda: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  8. Takahide Ito: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  9. Koichi Sohmiya: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  10. Masaaki Hoshiga: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
  11. Nobukazu Ishizaka: Department of Cardiology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. ishizaka@osaka-med.ac.jp.

Abstract

Serum levels of the soluble urokinase-type plasminogen activator receptor (suPAR) reflect immune and inflammatory activation, and are shown to be associated with cardiovascular outcomes. We herein investigated the potential association between suPAR and left ventricular diastolic dysfunction among patients with preserved left ventricular ejection fraction (LVEF) and sinus rhythm. Among 291 patients who had sinus rhythm and an LVEF of ≥50% enrolled in the study, 26 (8.9%) were considered to have diastolic dysfunction. patients with diastolic dysfunction had lower estimated glomerular filtration rate (eGFR), and higher systolic blood pressure (BPs), BNP, C-reactive protein, and suPAR than those without diastolic dysfunction. As compared with the first suPAR quartile, the fourth suPAR quartile was significantly associated with both diastolic dysfunction with an odds ratio of 8.95 [95% confidence interval (CI), 1.04-77.0, P < 0.05] after adjusting for sex, age, BPs log(eGFR), CRP, and diuretic use. On the other hand, receiver-operating characteristic curve (ROC) analysis showed that addition of log(suPAR) to the combination of age, sex, and log(eGFR), CRP, and diuretic use did not significantly improve the prediction of diastolic dysfunction. Among cardiac patients with preserved LVEF, serum suPAR was associated with diastolic dysfunction independent of confounding factors by logistic regression analysis. However, according to the ROC analysis, the utility of suPAR as a biomarker for diastolic dysfunction may be limited from a clinical point of view.

Keywords

References

  1. Am J Kidney Dis. 2009 Jun;53(6):982-92 [PMID: 19339088]
  2. Atherosclerosis. 2012 Feb;220(2):502-5 [PMID: 22119508]
  3. Heart Vessels. 2016 Jan;31(1):66-73 [PMID: 25223536]
  4. Curr Pharm Des. 2011;17(19):1924-43 [PMID: 21711238]
  5. Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1195-201 [PMID: 24099726]
  6. J Am Coll Cardiol. 2017 Mar 21;69(11):1451-1464 [PMID: 28302294]
  7. Am J Cardiol. 2014 Jan 15;113(2):321-327 [PMID: 24262762]
  8. PLoS One. 2017 Jan 30;12 (1):e0170546 [PMID: 28135310]
  9. J Am Coll Cardiol. 2011 Feb 15;57(7):861-9 [PMID: 21310324]
  10. Expert Rev Clin Immunol. 2014 Oct;10(10):1349-56 [PMID: 25142036]
  11. Int Heart J. 2016 Dec 2;57(6):729-735 [PMID: 27829641]
  12. Int J Cardiol. 2013 Aug 10;167(3):781-5 [PMID: 22459389]
  13. Am J Emerg Med. 2016 Mar;34(3):375-80 [PMID: 26615223]
  14. Eur J Heart Fail. 2016 Jan;18(1):103-12 [PMID: 26635076]
  15. Atherosclerosis. 2015 Mar;239(1):55-60 [PMID: 25574858]
  16. Ann Nucl Med. 2013 Oct;27(8):729-36 [PMID: 23712332]
  17. Circ J. 2012;76(3):607-11 [PMID: 22156312]
  18. Liver Int. 2012 Mar;32(3):500-9 [PMID: 22098627]
  19. Biomed Pharmacother. 2013 Mar;67(2):179-82 [PMID: 23201006]
  20. Eur Heart J. 2007 Oct;28(20):2539-50 [PMID: 17428822]
  21. Circ Res. 2016 Jun 24;119(1):159-76 [PMID: 27340274]
  22. Int J Cardiol. 2013 Sep 10;167(6):2904-11 [PMID: 22909410]
  23. Acta Oncol. 2010 Aug;49(6):805-11 [PMID: 20524776]
  24. Heart Vessels. 2016 Apr;31(4):499-507 [PMID: 25673497]
  25. ESC Heart Fail. 2016 Mar;3(1):53-59 [PMID: 27774267]
  26. N Engl J Med. 2015 Nov 12;373(20):1916-25 [PMID: 26539835]
  27. Eur J Heart Fail. 2016 Jun;18(6):588-98 [PMID: 26861140]
  28. Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H986-94 [PMID: 26209055]
  29. Heart Lung Circ. 2015 Mar;24(3):298-305 [PMID: 25456503]
  30. Eur J Heart Fail. 2014 Apr;16(4):377-83 [PMID: 24464777]
  31. Hypertension. 2000 Jan;35(1 Pt 1):6-12 [PMID: 10642267]
  32. JACC Heart Fail. 2016 Apr;4(4):312-24 [PMID: 26682792]
  33. Eur J Endocrinol. 2016 Jun;174(6):745-53 [PMID: 26951602]
  34. Expert Opin Ther Targets. 2016;20(5):551-66 [PMID: 26667094]
  35. Intensive Care Med. 2012 Sep;38(9):1418-28 [PMID: 22706919]
  36. Can J Cardiol. 2015 Oct;31(10):1293-302 [PMID: 26118447]
  37. J Am Coll Cardiol. 2006 Mar 7;47(5):962-8 [PMID: 16516078]
  38. J Am Coll Cardiol. 2013 Jul 23;62(4):263-71 [PMID: 23684677]
  39. PLoS One. 2016 Jul 11;11(7):e0156860 [PMID: 27400031]
  40. Circulation. 1977 Apr;55(4):613-8 [PMID: 138494]
  41. J Cardiol. 2014 Mar;63(3):198-204 [PMID: 24012332]
  42. Sci Rep. 2016 Dec 19;6:39481 [PMID: 27991579]
  43. Atherosclerosis. 2014 Nov;237(1):60-6 [PMID: 25222341]
  44. Heart Vessels. 2016 Apr;31(4):563-7 [PMID: 25712607]
  45. Am J Hypertens. 1993 Jun;6(6 Pt 2):211S-215S [PMID: 8347321]
  46. J Card Fail. 2015 Feb;21(2):167-77 [PMID: 25459685]
  47. J Am Heart Assoc. 2014 Oct 23;3(5):e001118 [PMID: 25341887]

MeSH Term

Aged
Biomarkers
Diastole
Echocardiography
Female
Follow-Up Studies
Heart Ventricles
Humans
Male
ROC Curve
Receptors, Urokinase Plasminogen Activator
Retrospective Studies
Stroke Volume
Ventricular Dysfunction, Left
Ventricular Function, Left

Chemicals

Biomarkers
Receptors, Urokinase Plasminogen Activator

Word Cloud

Created with Highcharts 10.0.0dysfunctionsuPARdiastolicpatientsassociatedpreservedLVEFeGFRloganalysisurokinase-typeplasminogenactivatorreceptorleftventricularamongejectionfractionsinusrhythmAmong8BPsquartilesignificantlysexageCRPdiureticuseROCcardiacbiomarkerSerumlevelssolublereflectimmuneinflammatoryactivationshowncardiovascularoutcomeshereininvestigatedpotentialassociation291≥50%enrolledstudy269%consideredPatientslowerestimatedglomerularfiltrationratehighersystolicbloodpressureBNPC-reactiveproteinwithoutcomparedfirstfourthoddsratio95[95%confidenceintervalCI104-770P < 005]adjustinghandreceiver-operatingcharacteristiccurveshowedadditioncombinationimprovepredictionserumindependentconfoundingfactorslogisticregressionHoweveraccordingutilitymaylimitedclinicalpointviewAssociationDiastolicInflammatorySoluble

Similar Articles

Cited By (5)